For PCR/RFLP studies, the control group was cephalomyopathy as well as in two other people increased to 97 subjects. No control subject or with symptoms indicative of mitochondrial dispatient with NIDDM had clinically obvious ease.6 The mutation at 5656 bp alters a single features of mitochondrial disease, although de-nucleotide at the site of mitochondrial trantailed screening such as audiometry and EMG script scission and further studies will be rewere not carried out. One pedigree with dia-quired to determine whether this might betes and deafness, previously reported to har-interfere with tRNA processing. The G to A bour the 3243 bp mtDNA mutation, and one mutation at 15927 bp in the tNRAthr was found subject without diabetes but with a hetero-in 3/124 NIDDM patients but 0/97 controls. patient with hypertrophic cardiomyopathy and a second patient with chronic external ophthalmoplegia.' The mutation occurs in the anticodon stem of the tRNA molecule and may adversely effect the tertiary structure required for mRNA binding. Evidence for this structural alteration arises from the large SSCP mobility shifts between the three distinct mtDNA base pair substitutions identified in the tRNA Ir gene (fig 2) . We detected a homoplasmic mutation at 7476 bp in one diabetic patient and two controls. This mutation lies close to others reported in patients with maternally inherited deafness.89 The significance of this finding is unclear since we did not screen our subjects for deafness.
Review of the clinical notes of patients with NIDDM failed to show any unusual phenotypic characteristics in those subjects with the homoplasmic mtDNA variants discussed above. However, detailed studies (for example, audiometry, echocardiography) will have to be performed in these patients and their relatives in order to define the importance of the mtDNA sequences observed. The results of this study suggest that in patients with NIDDM, heteroplasmic pathogenic mutations are rare within the regions of the mitochondrial genome we have studied. It is still possible that pathogenic mutations are present in other parts of the mitochondrial genome. Further studies are also required to determine whether acquired, somatic mtDNA defects in pancreatic beta cells play a role in the development of the disease. 
